← All organizations
Highest phase reached
Phase 4
First clinical trial
Jul 1, 1997First marketed drug
Sep 17, 2009First NDA
Oct 20, 2015Last known activity
Jun 19, 2018
Timeline
1950s
- Jan 1, 1954
Bio Products Laboratory— Founded
2000s
- Sep 17, 2009
immune globulin (human)— NDA Secondary Org
2010s
- Oct 20, 2015
human coagulation factor x— NDA Organization
Drugs by trial phase (9 distinct, 27 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (4 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Agammaglobulinemia
- Asperger Syndrome
- Autism Spectrum Disorder
- Autistic Disorder
- Common Variable Immunodeficiency
- Developmental Disabilities
- Disease
- Factor X Deficiency
- Hemophilia A
- Hemophilia B
- Hyper-IgM Immunodeficiency Syndrome
- Hyper-IgM Immunodeficiency Syndrome, Type 1
- Immunologic Deficiency Syndromes
- Neoplasm Metastasis
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Rabies
- Syndrome
- von Willebrand Diseases
- Wiskott-Aldrich Syndrome
Marketed drugs (3)
Recent trials (33)
- NCT03264157Lead sponsorPhase 2/Phase 3Dec 8, 2017
- NCT03264157Study directorPhase 2/Phase 3Dec 8, 2017
- NCT01884311Study directorPhase 3Aug 1, 2015
- NCT01884311Lead sponsorPhase 3Aug 1, 2015
- NCT01721681Lead sponsorPhase 3Apr 1, 2015
- NCT01963143Study directorPhase 3Feb 1, 2014
- NCT01963143Lead sponsorPhase 3Feb 1, 2014
- NCT01811875Study directorPhase 4Jun 1, 2013
- NCT01811875Lead sponsorPhase 4Jun 1, 2013
- NCT02199925CollaboratorPhase 4Jun 1, 2013
- NCT01086852Overall official - principal investigatorPhase 3Mar 1, 2011
- NCT01289847Lead sponsorPhase 4Mar 1, 2011
- NCT01086852Lead sponsorPhase 3Mar 1, 2011
- NCT00930176Lead sponsorPhase 3Jan 1, 2010
- NCT00504075Lead sponsorPhase 3Sep 1, 2007
Details
- Founded
- Elstree, GB Jan 1, 1954
- First NDA
- Oct 20, 2015
- Last known activity
- Jun 19, 2018
Designations held
- Orphan drug